Department of Medicine, Université de Genève, Geneva, Switzerland
Department of Internal Medicine, Neuchâtel Hospital Network, Neuchâtel, Switzerland.
BMJ Open. 2022 Aug 5;12(8):e053632. doi: 10.1136/bmjopen-2021-053632.
Patients with acute congestive heart failure (HF) regularly undergo urinary catheterisation (UC) at hospital admission. We hypothesised that UC has no clinical benefits with regard to weight loss during inpatient diuretic therapy for acute congestive HF and increases the risk of urinary tract infection (UTI).
Retrospective, non-inferiority study.
Geneva University Hospitals' Department of Medicine, a tertiary centre.
In a cohort of HF patients, those catheterised within 24 hours of diuretic therapy (n=113) were compared with non-catheterised patients (n=346).
The primary endpoint was weight loss 48 hours after starting diuretic therapy. Secondary endpoints were time needed to reach target weight, discontinuation of intravenous diuretics and resolution of respiratory failure. Complications included the time to a first UTI, first hospital readmission and death.
A total of 48-hour weight loss was not statistically different between groups and the adjusted difference was below the non-inferiority boundary of 1 kg (0.43 kg (95% CI: -0.03 to 0.88) in favour of UC, p<0.01 for non-inferiority). UC was not associated with time to reaching target weight (adjusted HR 1.0; 95% CI: 0.7 to 1.5), discontinuation of intravenous diuretics (aHR 0.9; 95% CI: 0.7 to 1.2) or resolution of respiratory failure (aHR 1.1; 95% CI: 0.5 to 2.4). UC increased the risk of UTI (aHR 2.5; 95% CI: 1.5 to 4.2) but was not associated with hospital readmission (aHR 1.1; 95% CI: 0.8 to 1.4) or 1-year mortality (aHR 1.4; 95% CI: 1.0 to 2.1).
In this retrospective study, with no obvious hourly diuresis-based diuretic adjustment strategy, weight loss without UC was not inferior to weight loss after UC within 24 hours of initiating diuretic treatment. UC had no impact on clinical improvement and increased the risk of UTI. This evidence, therefore, argues against the systematic use of UC during a diuretic therapy for HF.
急性充血性心力衰竭(HF)患者经常在入院时接受导尿(UC)。我们假设 UC 对急性充血性 HF 患者在住院利尿剂治疗期间的体重减轻没有临床益处,并且增加了尿路感染(UTI)的风险。
回顾性非劣效性研究。
日内瓦大学医院内科,三级中心。
在 HF 患者队列中,那些在利尿剂治疗后 24 小时内进行导尿的患者(n=113)与未进行导尿的患者(n=346)进行比较。
主要终点是开始利尿剂治疗后 48 小时的体重减轻。次要终点是达到目标体重所需的时间、停止静脉利尿剂和呼吸衰竭的缓解。并发症包括首次 UTI、首次住院再入院和死亡的时间。
两组之间 48 小时的体重减轻没有统计学差异,调整后的差异低于 1 公斤的非劣效性边界(0.43 公斤(95%CI:-0.03 至 0.88)有利于 UC,p<0.01 为非劣效性)。UC 与达到目标体重的时间无关(调整后的 HR 1.0;95%CI:0.7 至 1.5)、停止静脉利尿剂(调整后的 HR 0.9;95%CI:0.7 至 1.2)或呼吸衰竭的缓解(调整后的 HR 1.1;95%CI:0.5 至 2.4)。UC 增加了 UTI 的风险(调整后的 HR 2.5;95%CI:1.5 至 4.2),但与住院再入院(调整后的 HR 1.1;95%CI:0.8 至 1.4)或 1 年死亡率(调整后的 HR 1.4;95%CI:1.0 至 2.1)无关。
在这项回顾性研究中,没有明显的基于每小时尿量的利尿剂调整策略,在开始利尿剂治疗后 24 小时内不进行 UC 的体重减轻并不逊于 UC 后的体重减轻。UC 对临床改善没有影响,但增加了 UTI 的风险。因此,这一证据反对在 HF 的利尿剂治疗期间系统使用 UC。